DRG 849 Overview

DRG 849 covers inpatient episodes related to radiotherapy, including administration and management of external beam radiation and other therapeutic radiation techniques when billed as the principal reason for admission. This Diagnosis-Related Group is focused on the clinical resources and inpatient care associated with delivering radiation treatments and managing acute effects. It matters for Medicare payment because hospital reimbursement is grouped by the principal inpatient reason and associated resource use under the Diagnosis-Related Group system. Accurate classification affects hospital payment eligibility and billing for radiotherapy services.

• Trials comparing radiation delivery techniques (for example, conventional external beam radiotherapy versus intensity-modulated or stereotactic approaches) for patients with localized solid tumors requiring inpatient radiotherapy: these studies focus on dose conformity, treatment duration, and acute toxicity profiles in populations with tumors that prompt hospital admission (e.g., symptomatic head and neck, spine metastases causing cord compression). They address clinical questions about balancing rapid symptom control and minimizing short-term side effects, which is directly relevant to inpatient workflows, length of stay, and resource utilization for payers.
• Studies of radiotherapy combined with systemic therapies in the preoperative or neoadjuvant setting for patients who are hospitalized for complex oncologic care: these trials examine sequencing, timing, and safety of concurrent or sequential modalities in patients with locally advanced cancers who may require inpatient management for treatment-related complications. Results inform clinical decision-making about coordination of inpatient services, predicted complication rates, and expected downstream costs tied to multimodality treatment.
• Observational and outcomes research on quality metrics, readmissions, and palliative radiotherapy effectiveness in patients receiving inpatient radiotherapy for symptom control (for example, pain from bone metastases or bleeding tumors): these studies characterize real-world effectiveness, symptom relief durability, and predictors of 30‑day readmission or emergency care among frail or comorbid inpatients. Findings are relevant to providers for optimizing discharge planning and to payers for understanding cost drivers, episode-of-care boundaries, and opportunities to reduce avoidable utilization.